Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
Status:
Completed
Trial end date:
2012-11-09
Target enrollment:
Participant gender:
Summary
This phase I clinical trial is studying the side effects and the best dose of lenalidomide
after donor bone marrow transplant in treating patients with high-risk hematologic cancer.
Biological therapies, such as lenalidomide, may stimulate the immune system in different ways
and stop cancer cells from growing.